| KODIAK SCIENCES DL-,0001 |
| USA |
| Gesundheit |
| US50015M1099 / A2N6P0 |
| K27 (Frankfurt) / KOD (NASDAQ) |
| FRA:K27, ETR:K27, K27:GR, NASDAQ:KOD |
| - |
| https://kodiak.com/ |
|
Kodiak Sciences Inc. is a biopharmaceutical company focused on developing innovative therapies to treat retinal diseases. Leveraging its proprietary Antibody Biopolymer Conjugate (ABC) platform, Kodia..
>Volltext.. |
| 1169.86 Mio. EUR |
| 1246.75 Mio. EUR |
| - |
| -167.78 Mio. EUR |
| -187.26 Mio. EUR |
| -3.55 EUR |
| 139.76 Mio. EUR |
| 62.07 Mio. EUR |
| -109.17 Mio. EUR |
| 1.7 |
| - |
| -7.62% |
| - |
| - |
| - |
| - |
| KODIAK SCIENCES |
| 26.03.26 |
|
||||
|
||||
|